FLT3 and acute myeloid leukemia: Notably, responses were observed in 9 out of 11 patients with AML harboring a FMS-like tyrosine kinase-3 (FLT3) receptor internal tandem duplication (ITD), with an ORR of 82% and a cCR of 64%.